Eli Lilly Message Board - Msg: 32940789

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly

LLY 1,042

-1.2%

Dec 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Moonray	9/19/2020 1:31:02 PM
	of 642

Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies Eli Lilly & Company LLY signed a global manufacturing collaboration with Amgen AMGN to increase the supply capacity of COVID-19 antibody therapies that Lilly is currently developing. Lilly is making rigorous efforts to develop several potential neutralizing ntibodies for the treatment COVID-19. It is developing an antibody therapy candidate LYCoV555 in collaboration with AbCellera. Interim data fromthe phase II study (BLAZE-1) evaluating LY-CoV555 to treat mild-to-moderate recently-diagnosed COVID-19 patients was released this week. The study met the primary endpoint. Interim results from the same showed that treatment with LY-CoV555 led to a reduced rate of hospitalization for patients while consistent effects of viral reduction were seen at earlier time points. Additionally, Lilly is conducting a separate phase III study on LYCoV555 for the prevention of COVID-19 at nursing homes Lilly also has a separate collaboration with China-based Junshi Biosciences to co-develop therapeutic antibodies for COVID-19. The companies have completed dosing in a phase I study on LY-CoV016, the lead antibody from the alliance. Further, Lilly is conducting a phase II study on an antibody that targets Angiopoietin 2, which has been observed to be elevated in COVID-19 patients with acute respiratory distress syndrome or ARDS. The Amgen agreement will allow Lilly to increase production of the antibody therapies if any of the above candidates gets a regulatory approval. Lilly’s stock has risen 16% this year so far against its industry’s increase of 0.9%. More at: finance.yahoo.com o~~~ O

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next